Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 7,061 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Terminated Phase 2 Interventional Results available

Ruxolitinib in Patients With Breast Cancer

NCT01562873
View directory record Official record
Conditions
Breast Cancer
Interventions
Ruxolitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 27, 2026, 3:34 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866
View directory record Official record
Conditions
Solid Tumors
Interventions
Bemarituzumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Breast Cancer

NCT00004156
View directory record Official record
Conditions
Breast Cancer
Interventions
MUC1-KLH vaccine/QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 27, 2026, 3:34 PM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Completed No phase listed Observational

Adherence to Intensive Surveillance for Hereditary Breast Cancer

NCT00582803
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2009 · Synced Oct 27, 2026, 3:34 PM EDT
Not listed Phase 2 Interventional

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

NCT01221870
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Tesetaxel once every 3 weeks, Tesetaxel once weekly
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
New York, New York • Greensboro, North Carolina • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 27, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

NCT03909282
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ
Interventions
Lumpectomy, Partial breast irradiation prior to surgery
Procedure · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer, Pain, Prostate Cancer
Interventions
pain therapy, radiation therapy
Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
234
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 27, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT03927027
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Isosulfan Blue, Axillary Lymph Node Dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • La Jolla, California • Martinez, California + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Not listed Phase 2 Interventional

Phase II Study in Patients With Operable Breast Cancer

NCT00518583
View directory record Official record
Conditions
Breast Cancer
Interventions
Pegylated Liposomal Doxorubicin (Doxil)
Drug
Lead sponsor
Aptium Oncology Research Network
Network
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Burbank, California • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00470301
View directory record Official record
Conditions
Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
tipifarnib, paclitaxel, doxorubicin, cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Tampa, Florida • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 27, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

NCT05933395
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Not applicable Interventional

EHR-embedded OCDT in Breast or GI Cancer

NCT03858712
View directory record Official record
Conditions
Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions
Active Care Team Alert, Passive Care Team Alert
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 27, 2026, 3:34 PM EDT
Withdrawn Phase 2 Interventional

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

NCT04419181
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 3:34 PM EDT
Not listed No phase listed Observational

NSABP Biospecimen Discovery Project

NCT01850628
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 27, 2026, 3:34 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171
View directory record Official record
Conditions
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions
AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 3:34 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

NCT00896636
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
Random fine need aspiration (rFNA), Mammogram
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Study of Support Groups for African-American Breast Cancer Survivors

NCT00949871
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor
Interventions
communication analysis, questionnaire administration, psychosocial assessment and care, support group therapy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

NCT01765309
View directory record Official record
Conditions
Breast Cancer
Interventions
Bilateral mastectomy with reconstruction
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 27, 2026, 3:34 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

NCT00522457
View directory record Official record
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
ertumaxomab
Drug
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota • Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2011 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NCT01234012
View directory record Official record
Conditions
Solid Tumor
Interventions
IMF-001
Biological
Lead sponsor
ImmunoFrontier, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Not applicable Interventional

A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ

NCT01628536
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Black cohosh
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 27, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

NCT01129336
View directory record Official record
Conditions
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Interventions
Zoledronic acid, Standard Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 27, 2026, 3:34 PM EDT